RxDoctor Payments Data

Louis Cox, MD

Internal Medicine · Oklahoma City, OKNPI 1164538872

Payments from drug & device makers

$1,201in general payments, 2019–2025

Across 70 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$223
  • AbbVie$204
  • Pfizer$132
  • GSK$129
  • Lilly USA, LLC$88
  • Amgen$75
  • plus $351 from 9 others

What the payments were for

  • Food & beverage$1,201100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,201 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$403,977
Medicare patients
692
Services billed
5,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$143,815
JardianceEmpagliflozin50$64,522
GlyxambiEmpagliflozin/Linagliptin45$55,730
EliquisApixaban36$45,299
XareltoRivaroxaban31$30,234
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,836
Tresiba Flextouch U-200Insulin Degludec17$14,767
UbrelvyUbrogepant12$14,432
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,313
Advair HfaFluticasone Propion/Salmeterol16$5,879
Dexlansoprazole DrDexlansoprazole20$4,830
Atorvastatin Calcium280$4,262
SymbicortBudesonide/Formoterol Fumarate12$3,943
Levothyroxine Sodium276$3,017
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen109$2,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$223$143,815100 claims
Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat$28$126,565108 claims
PfizerEliquis$132$45,29936 claims
GSKTrelegy Ellipta$129$17,83626 claims
AbbVieUbrelvy$204$14,43212 claims
AstraZenecaSymbicort$31$3,94312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →